Nichi-Iko Offers Heartfelt Apology As It Forecasts Huge Annual Loss
As Analyst Warns: Pharmacies And Medical Institutions ‘May Start To Desert Nichi-Iko’
Nichi-Iko’s first-half financial results made for unhappy reading again as the company’s bottom line was battered by longstanding quality problems, leading the firm to announce huge projected losses for its current financial year ending in March 2022.
You may also be interested in...
Rivals to Careram, Keppra, Patanol, Velcade and Volibris have been listed with Japan’s NHI drug price list by Sawai, as the company seeks to capitalize on its position as a leading supplier in the market.
Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.
Towa has issued a minor upward revision to its full-year guidance after its domestic business delivered higher than expected sales and profit growth during H1, but uncertainty in the Japanese generics market and concerns over the firm’s overseas units have led some analysts to raise questions.